Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $10.63 USD
Change Today +0.11 / 1.05%
Volume 121.4K
NSTG On Other Exchanges
Symbol
Exchange
NASDAQ GM
As of 8:10 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

nanostring technologies inc (NSTG) Snapshot

Open
$10.56
Previous Close
$10.52
Day High
$10.81
Day Low
$10.47
52 Week High
04/2/14 - $21.87
52 Week Low
10/13/14 - $7.80
Market Cap
195.2M
Average Volume 10 Days
94.2K
EPS TTM
$-2.90
Shares Outstanding
18.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NANOSTRING TECHNOLOGIES INC (NSTG)

Related News

No related news articles were found.

nanostring technologies inc (NSTG) Related Businessweek News

No Related Businessweek News Found

nanostring technologies inc (NSTG) Details

NanoString Technologies, Inc. develops, manufacture, and sells products that unlock scientifically valuable and clinically actionable genomic information from minute amounts of tissue. The company provides nCounter Analysis System, an automated, multi-application, digital detection, and counting system that includes nCounter Prep Station, an automated liquid handling component for processing and preparing the samples for data collection; and nCounter Digital Analyzer, which collects data from samples through the images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nSolver Analysis software, a data analysis program that offers researchers the ability to quality check, normalize, and analyze their data. In addition, it provides Pan Cancer pathways gene expression panels, PanCancer immune profiling gene expression panels, gene expression panels, miRNA expression panels, and cancer copy number variation panels; custom CodeSets; and master kits that include ancillary reagents and plasticware to setup and process samples in the nCounter Prep Station and nCounter Digital Analyzer. It markets its systems and related consumables to researchers in academic, government, and biopharmaceutical laboratories for use in understanding fundamental biology and the molecular basis of diseases, as well as to clinical laboratories and medical centers for diagnostic use in North America, Europe, the Middle East, and the Asia Pacific. The company was founded in 2003 and is headquartered in Seattle, Washington.

276 Employees
Last Reported Date: 03/13/15
Founded in 2003

nanostring technologies inc (NSTG) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $441.8K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $349.2K
Senior Vice President of Operations & Adminis...
Total Annual Compensation: $325.0K
Senior Vice President of Research & Developme...
Total Annual Compensation: $293.7K
Compensation as of Fiscal Year 2014.

nanostring technologies inc (NSTG) Key Developments

NanoString Technologies, Inc. Appoints Robert Hershberg to its Board of Directors

NanoString Technologies, Inc. has appointed Robert Hershberg to its board of directors. Dr. Hershberg brings to the Board extensive executive and board level expertise in the fields of immuno-oncology and translational medicine, as well as a passion for the advancement of early cancer screening technologies. He joined Celgene Corporation in July 2014 as Senior Vice-President of Immuno-Oncology. Dr. Hershberg is also the founder, President and CEO of VentiRx Pharmaceuticals, Inc. and serves as an independent member of the Board of Directors of Adaptive Biotechnologies Corp. Previously, he was Chief Medical Officer of Dendreon Corporation, and vice president, Medical Genetics of Corixa Corporation.

NanoString Technologies Appoints Robert Hershberg to Board of Directors

NanoString Technologies, Inc. announced that Robert Hershberg has been appointed to its Board of Directors, effective March 2, 2015. The Board now consists of six members. He joined Celgene Corporation, a publicly-traded biopharmaceutical company, in July 2014 as Senior Vice-President of Immuno-Oncology and currently leads Celgene's research and early development efforts across its immuno-oncology portfolio. He also oversees the newly formed Celgene Immuno-Oncology Center of Excellence in Seattle, Washington, which is focused on Translational Medicine ranging from basic immunology/biomarker development, immuno-profiling, systems immunology and early clinical development of existing and novel compounds.

NanoString Technologies, Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Earnings Guidance for the Year 2015

NanoString Technologies, Inc. announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported total revenue of $15,618,000 against $10,120,000 a year ago. Loss from operations was $11,506,000 against $8,301,000 a year ago. Net loss attributable to common stockholders was $12,380,000 or $0.68 basic and diluted per share against $8,827,000 or $0.60 basic and diluted per share a year ago. Net loss (non-GAAP) was $9,742,000 or $0.53 basic and diluted per share against $7,499,000 or $0.51 basic and diluted per share a year ago. For the year, the company reported total revenue of $47,593,000 against $31,403,000 a year ago. Loss from operations was $46,023,000 against $28,497,000 a year ago. Net loss attributable to common stockholders was $50,038,000 or $2.80 basic and diluted per share against $33,934,000 or $4.44 basic and diluted per share a year ago. Net loss (non-GAAP) was $39,433,000 or $2.21 basic and diluted per share against $25,571,000 or $2.14 basic and diluted per share a year ago. The company provided earnings guidance for the year 2015. For the year, the company expects total revenue in the range of $58 million to $61 million, gross margin in the range of 53% to 55%, operating expenses in the range of $77 million to $81 million and operating loss in the range of $43 million to $49 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NSTG:US $10.63 USD +0.11

NSTG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Enzo Biochem Inc $2.88 USD -0.12
Exiqon A/S kr8.80 DKK 0.00
Pacific Biosciences of California Inc $5.59 USD +0.17
Response Genetics Inc $0.45 USD -0.0065
WaferGen Bio-systems Inc $4.35 USD -0.03
View Industry Companies
 

Industry Analysis

NSTG

Industry Average

Valuation NSTG Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.1x
Price/Book 4.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NANOSTRING TECHNOLOGIES INC, please visit www.nanostring.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.